Boston’s biotech scene got a jolt on Thursday, April 30, 2026, as Avalyn Pharma stormed onto the public markets with an upsized IPO that investors devoured. The company priced its offering at $18 a share, sold about 16.7 million shares to raise roughly $300 million, then watched the stock rip about 64% higher to close at $29.49 on day one. The fresh cash is earmarked for Avalyn’s inhaled drug programs for pulmonary fibrosis as it pushes ahead in Phase 2 trials, a development that has not gone unnoticed by local investors focused on respiratory therapies.
Deal Terms And Who Ran The Offering
Avalyn said it upsized the deal to 16,666,667 shares at $18 apiece and granted underwriters a 30-day option to buy up to 2.5 million additional shares, according to a press release via BioSpace. The company said the offering is expected to close on May 1 and that the shares would trade on the Nasdaq Global Select Market under the ticker AVLN, with Morgan Stanley, Jefferies, Evercore ISI and Guggenheim listed as joint book-running managers.
Market Reaction On Day One
Trading data show Avalyn wrapped up its first session at $29.49, roughly a 64% gain over the $18 IPO price, with an intraday range that came close to $30, according to market pages on Investing.com. Volume was hefty for a fresh listing, a sign that investors were eager to get exposure to the company’s lung-targeted strategy.
What Avalyn Is Developing
The company is working on inhaled formulations of already approved antifibrotic drugs: AP01 (pirfenidone) and AP02 (nintedanib), plus an inhaled combination dubbed AP03. It describes AP01 as being evaluated in the global Phase 2b MIST trial, according to its SEC registration statement. The S-1 outlines plans to use IPO proceeds to drive these clinical programs and support later-stage development while aiming to limit systemic side effects through lung-targeted delivery.
Why Investors Piled In
Underwriters bumped up the offering size from the initial share count after Avalyn came to market with a deep bench of venture and crossover backers that helped fuel pre-IPO demand. Axios’ Pro Rata newsletter cites investors including F-Prime, Eventide, Norwest Venture Partners, Novo Holdings and Perceptive Advisors among others, a lineup that analysts say helped stoke interest ahead of the debut.
Local Biotech Context And What Is Next
The Avalyn IPO slots into a busy streak of Boston and Cambridge life sciences firms heading to public markets, a trend that local outlets have been chronicling, including reporting from the Boston Business Journal. As the offering moves toward its expected May 1 close, Avalyn has said it plans to use the funds to advance its MIST and AURA trials and gear up for later-stage work, according to the company’s release.
